D espite guideline-recommended therapy for patients with heart failure (HF), morbidity and mortality rates remain unacceptably high. 1 Given the public health burden of HF, there is a clear need for improved therapies. A growing body of evidence suggests that increased oxidative stress contributes to ventricular and vascular remodeling and disease progression in HF. 2 Xanthine oxidase (XO) is a potential source Background-Oxidative stress may contribute to heart failure (HF) progression. Inhibiting xanthine oxidase in hyperuricemic HF patients may improve outcomes. Methods and Results-We randomly assigned 253 patients with symptomatic HF, left ventricular ejection fraction ≤40%, and serum uric acid levels ≥9.5 mg/dL to receive allopurinol (target dose, 600 mg daily) or placebo in a double-blind, multicenter trial. The primary composite end point at 24 weeks was based on survival, worsening HF, and patient global assessment. Secondary end points included change in quality of life, submaximal exercise capacity, and left ventricular ejection fraction. Uric acid levels were significantly reduced with allopurinol in comparison with placebo (treatment difference, -4.2 [-4.9, -3.5] mg/dL and -3.5 [-4.2, -2.7] mg/dL at 12 and 24 weeks, respectively, both P<0.0001). At 24 weeks, there was no significant difference in clinical status between the allopurinol-and placebo-treated patients (worsened 45% versus 46%, unchanged 42% versus 34%, improved 13% versus 19%, respectively; P=0.68). At 12 and 24 weeks, there was no significant difference in change in Kansas City Cardiomyopathy Questionnaire scores or 6-minute walk distances between the 2 groups. At 24 weeks, left ventricular ejection fraction did not change in either group or between groups. Rash occurred more frequently with allopurinol (10% versus 2%, P=0.01), but there was no difference in serious adverse event rates between the groups (20% versus 15%, P=0.36). Conclusions-In high-risk HF patients with reduced ejection fraction and elevated uric acid levels, xanthine oxidase inhibition with allopurinol failed to improve clinical status, exercise capacity, quality of life, or left ventricular ejection fraction at 24 weeks. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00987415.
of oxidative stress and may be an important target for therapy. 3 During purine metabolism, increased XO activity leads to the production of superoxide and uric acid (UA). Significant hyperuricemia is present in ≈25% of patients with HF and reduced ejection fraction, 4, 5 and it is associated with worsening symptoms, exercise intolerance, and reduced survival. [6] [7] [8] Serum UA levels are included in HF risk scores 8, 9 and may help to select high-risk patients for XO inhibition.
Allopurinol is a potent inhibitor of XO that may reverse several pathophysiological processes in HF, including decreased calcium sensitivity, mechanoenergetic uncoupling, increased anaerobic metabolism, and energy depletion. 10 Studies in animals and humans with HF have shown that allopurinol can increase myocardial efficiency and reduce oxygen consumption. 11, 12 Magnetic resonance spectroscopy has demonstrated that allopurinol increases myocardial high-energy phosphates and adenosine triphosphate flux, thereby improving mechanoenergetic coupling. 13 Impaired endothelial function improves in a dose-dependent fashion with chronic XO inhibition in HF, 14, 15 and observational studies in HF patients with gout suggest that treatment with allopurinol is associated with improved survival. [16] [17] [18] Notably, allopurinol use is treated as a marker of improved survival in the Seattle Heart Failure Model. 8 Hare et al 19 randomly assigned 405 patients with moderate to severe HF and reduced ejection fraction to 6 months of treatment with oxypurinol (the active metabolite of allopurinol) or placebo. Although oxypurinol had no clinical benefit in the overall study population, a subgroup of patients with hyperuricemia (UA level ≥9.5 mg/dL) responded favorably with improved clinical status and trends toward decreased all-cause and cardiovascular death. Based on these findings, we hypothesized that, in patients with symptomatic HF and reduced left ventricular ejection fraction (LVEF), who have elevated serum UA levels, treatment with high-dose allopurinol for 24 weeks would improve a composite clinical outcome of survival, worsening HF, and patient global assessment.
Methods

Study Oversight
Investigators from the National Heart, Lung, and Blood Institutesponsored Heart Failure Clinical Research Network conceived, designed, and conducted the Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) trial. The study protocol was approved by a National Heart, Lung, and Blood Institute-appointed protocol review committee, an independent data and safety monitoring board, and the institutional review board at each participating site. The Duke Clinical Research Institute served as the data-coordinating center. All patients provided written informed consent.
Study Design
Details of the study design, patient population, end points, and statistical considerations have been published. 20 EXACT-HF was a multicenter, 1:1 randomized, double-blind, placebo-controlled, 24-week trial of allopurinol in patients with symptomatic HF due to left ventricular (LV) systolic dysfunction (LVEF ≤40%) and elevated serum UA levels (≥9.5 mg/dL). Patients were required to have at least 1 additional high-risk marker, including an acute HF event (hospitalization or emergency department visit) within 12 months, 21 severe LV dysfunction (LVEF ≤25%), or an elevated natriuretic peptide level (B-type natriuretic peptide >250 pg/mL or N-terminal pro-B-type natriuretic peptide >1500 pg/mL). 22 Patients with estimated glomerular filtration rate <20 mL/min were excluded.
Study Drug, Randomization, and Blinding
Active therapy in EXACT-HF consisted of allopurinol (target dose, 600 mg daily), with dose adjustment for renal function ( Table I in the  online-only Data Supplement) . 20, 23 The study drug was given for 24 weeks starting with 300 mg by mouth once daily for 1 week, and if tolerated, increased to 600 mg daily. Patients unable to tolerate 600 mg were maintained on 300 mg. With the use of an automated system, patients were randomly assigned to treatment by using a permuted block randomization scheme stratified by clinical site. Study drug or matching placebo capsules were started within 12 hours of completing the baseline visit. Investigators were requested not to measure serum UA levels during the study.
Concomitant Medications and Gout
To be eligible to participate, patients had to be receiving a stable HF regimen for at least 2 weeks (3 months for β-blockers) before randomization. Intermittent use of supplemental diuretics was permitted. Patients with a history of gout could be enrolled as long as they were not currently being treated with, and unlikely to require, allopurinol during the study. If a patient was started on open-label allopurinol for gout, the study drug was permanently discontinued, but visits continued through 24 weeks.
Study End Points
The primary end point was a composite clinical end point (CCE) that classified a subject's clinical status as improved, worsened, or unchanged at 24 weeks, as previously described. 20, 24 This classification follows sequential rules based on: death; hospitalization, emergency department visit or emergent clinic visit for worsening HF; medication change for worsening HF (eg, addition of a new drug class or an by guest on August 31, 2017 http://circ.ahajournals.org/ Downloaded from increase in diuretic dose by at least 50% for >1 week); and Patient Global Assessment using a 7-point scale 25 (Table II in the online-only  Data Supplement) . Secondary end points at 12 and 24 weeks included changes in quality of life assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) 26 and submaximal exercise capacity assessed by 6-minute walk test (6MWT). 27 Additional end points included echocardiographic measures of LV remodeling including LV volumes, mass, and ejection fraction measured in a core laboratory (Mayo Clinic), biomarkers including UA, N-terminal pro-B-type natriuretic peptide, cystatin C, and myeloperoxidase measured in a core laboratory (University of Vermont), and time to first HF hospitalization (as determined by the investigator) and time to all-cause death or hospitalization. Myeloperoxidase was measured by using a quantitative sandwich enzyme immunoassay (Quantikine Human Myeloperoxidase Immunoassay; R&D Systems, Minneapolis, MN), with a detection range of 0.15 to 10 ng/mL and expected normal serum levels of 21 to 229 ng/mL. Samples were diluted to achieve values within the standard curve of the assay. Interassay and intra-assay coefficients of variation range from 1.5% to 2.6% and 8.2% to 10.8%, respectively.
Statistical Analysis and Power Calculation
All analyses were conducted by using the intention-to-treat principle and included all randomly selected patients ( Figure 1 ). Analysis of the primary CCE used the 1 degree-of-freedom Cochran-Mantel-Haenszel row mean score test with modified ridit scores to compare the distributions. Based on previous data, 19 we assumed that the placebo arm would have the following approximate response rates for the primary end point: 33% improved, 42% unchanged, and 25% worsened. We hypothesized that the outcome of the allopurinol arm would be superior, with response rates of ≈52% improved, 37% unchanged, and 11% worsened. Based on a simulation using 2000 data sets, we estimated that a sample size of 250 patients would provide 83% power to detect a statistically significant difference using the row mean score statistic with the assumptions above. The 2-sided type I error rate was set at 0.05. For the primary end point, there were no missing data. A prespecified analysis of the primary CCE stratified by baseline serum creatinine level (≤2 mg/dL versus >2 to ≤3 mg/dL) was also performed. Plus-minus values are means±SD. ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; BUN, blood urea nitrogen; LV, left ventricular; MR, mitral regurgitation; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; Q1, 25th percentile; Q3, 75th percentile; and SD, standard deviation. *All P values are >0.05 for comparisons of baseline characteristics between the groups, with the exceptions of ejection fraction (P=0.030) and amiodarone (P=0.017).
†Obtained at or within 4 weeks of screening. Changes from baseline in KCCQ scores, 6MWT distances, echocardiographic measures, and biomarkers between the 2 treatment groups were assessed at 12 and 24 weeks with adjustment for the baseline value with the use of an analysis of covariance approach. Missing values were handled using multiple imputation for all end points except echocardiographic measures. For the KCCQ overall summary score (9% missing data at 24 weeks), a total of 100 imputed data sets were used. The imputation model includes covariates for assigned treatment, renal function at baseline, age, sex, and nonmissing values for each of the KCCQ summary scores across all visits where KCCQ was completed. For the 6MWT (20% missing data at 24 weeks), a similar imputation approach was used and included adjustments for nonmissing walk distances at each time period. Cumulative event rates for death and hospitalization were estimated by using the Kaplan-Meier method. 28 For binary outcomes, odds ratios and 95% confidence intervals (CIs) were obtained from logistic regression models. Hazard ratios, 95% CIs, and P values for the comparison of the 2 treatment groups were determined with the use of the Cox regression model. 29 A 2-sided α-level of 0.05 was considered to indicate statistical significance. All data analyses were conducted with SAS software, version 9.2 or higher.
Results
Patients
Two hundred fifty-three patients were enrolled between May 2010 and June 2013 at 38 sites in the United States and Canada. Baseline demographic and clinical characteristics of the 2 treatment groups were similar ( Table 1 ). The median (25th, 75th percentile) age of the study population was 63 (53, 72) years and median LVEF was 25% (19, 33) . Eighty-two percent were men and 29% were black. Patients had mild-moderate symptoms of chronic HF (median duration, 5.2 [1.9, 10.1] years). Frequent comorbidities included diabetes mellitus 55%, hypertension 78%, and atrial fibrillation or flutter 49%. Hospitalization for HF in the past year was seen in 57%. Median UA level for the entire cohort was 11.1 (10.1, 12.1) mg/dL, and 23% of patients had a history of gout. Most patients were receiving guidelinerecommended pharmacological and device-based therapies, and were clinically stable (absence of rales 95%, trace or no edema 86%, jugular venous pressure <8 cm 71%). Data in columns 2 and 3 are presented as median (25th, 75th percentiles). Treatment difference is defined as allopurinol-placebo and was estimated by using an analysis of covariance on the 100 multiple imputation data sets. CI indicates confidence interval. 
Study Drug Administration
All patients, with the exception of 1 in the placebo group, were initiated on the study drug ( Figure 1) , and there were no differences between the 2 treatment groups in median dose achieved (300 [0, 600] mg in both groups) or rate of permanent study drug discontinuation (allopurinol 34%, placebo 28%). For patients with a baseline serum creatinine level ≤2 mg/dL, the maximum target dose of 600 mg was achieved in 85% of the allopurinol group and 83% of the placebo group. For patients with a baseline serum creatinine level >2 to ≤3 mg/dL, the maximum target dose of 300 mg was achieved in 65% and 75%, respectively. For patients who permanently discontinued the study drug, the median duration of treatment was 7.2 (2.6, 18.1) weeks. The final dose that patients were taking in the 2 treatment groups, stratified by baseline renal function, is provided in Table III in the online-only Data Supplement.
Primary End Point
At 24 weeks, there was no significant difference in the primary CCE between the allopurinol-and placebo-treated patients (worsened 45% versus 46%, unchanged 42% versus 34%, improved 13% versus 19%, respectively; P=0.68; Figure 2A) .
A prespecified analysis of the primary CCE stratified by baseline serum creatinine level (≤2 mg/dL [n=217] versus >2 to ≤3 mg/dL [n=36]) also showed no significant differences between the 2 groups (P=0.73 and P=1.00, respectively). Finally, a per protocol analysis that included only patients who were still taking study drug at the end of the study (or at the time of death) showed no difference in the primary CCE between groups (P=0.27).
Secondary End Points
At 12 and 24 weeks, there was no significant difference in changes in KCCQ overall summary score or 6MWT distance between the allopurinol-and placebo-treated patients ( 
Echocardiographic Measures
At 24 weeks, there was no significant difference in changes in LV volumes, mass, or ejection fraction between the allopurinol-and placebo-treated patients ( Table 2 ). For the entire cohort, there was little change in these measures over the study period (eg, LVEF median, 26% [20, 33] and 28% [21, 35] at baseline and 24 weeks, respectively).
Biomarkers
Serum UA levels decreased significantly with allopurinol in comparison with placebo ( Figure 2B , Table 3 ). Treatment differences (95% CI) were -4.2 (-4.9 to -3.5) mg/dL and -3.5 (-4.2 to -2.7) mg/dL at 12 and 24 weeks, respectively (both P<0.0001). At 24 weeks, 48% of the allopurinol-treated patients had serum UA levels <6 mg/dL in comparison with only 5% in the placebo group. With the exception of cystatin C at 12 weeks, there were no significant treatment differences in other core biomarkers between the 2 groups (Table 3 ). There was also no difference in change in other markers of renal function (serum creatinine, estimated glomerular filtration rate) measured in local laboratories between the treatment groups ( Table IV in 
Clinical Outcomes
There was no difference between the treatment groups in the proportion of patients who died (6%), were hospitalized for any cause (38%), or had an unscheduled outpatient visit during the study ( did not differ significantly between the 2 groups. Medication change for worsening HF occurred in 30% of the allopurinol group and 38% of the placebo group (odds ratio, 0.73; 95% CI, 0.43-1.23, P=0.23). At 24 weeks, 21% of the allopurinol-treated patients and 34% of the placebo group were moderately or markedly better on the Patient Global Assessment tool, but the overall treatment difference was not significant. Although there was no difference in the risk of death or hospitalization at 24 weeks between the 2 treatment groups ( Figure 4A ), HF hospitalization ( Figure 4B ) tended to be reduced in the allopurinol group (hazard ratio, 0.67; 95% CI, 0. 38-1.16, P=0.15 ).
Safety
Overall, study treatment was well tolerated (Table 5 ). There were fewer reports of gout in the allopurinol group (7% versus 11% placebo), but this did not reach statistical significance (P=0.23). Rash occurred more frequently in the allopurinol group (10% versus 2% placebo, P=0.01), whereas vascular events occurred more frequently in the placebo group (6% versus 2% allopurinol, P=0.04). There was no difference in the overall rate of adverse events (63% versus 58%; P=0.51) or serious adverse events (20% versus 15%; P=0.36) between the allopurinol and placebo groups, respectively.
Discussion
A large body of experimental and clinical data suggests that oxidative stress contributes to ventricular and vascular remodeling and disease progression in HF. XO is a potent source of oxidative stress, and therefore an obvious target for therapy. Accordingly, we studied a high-risk HF population with reduced ejection fraction and elevated serum UA levels. Contrary to our hypothesis, we found that XO inhibition with high-dose allopurinol had no detectable benefits on clinical status, exercise capacity, quality of life, or LV structure and function.
Previous clinical studies show acute and chronic benefits of allopurinol in HF, [12] [13] [14] [15] 30 and epidemiological data suggest an association between allopurinol use and improved outcomes in HF patients with gout. 18 Previous mechanistic studies in HF have shown that allopurinol improved coronary flow reserve, mechanoenergetic coupling, 12 myocardial adenosine triphosphate flux, 13 and vascular endothelial function. 15 We did not assess these physiological end points, and they may be poor surrogates for the clinical end points that we studied. However, enhanced endothelium-dependent vasodilation might be expected to improve exercise capacity, and direct myocardial and coronary vascular effects should improve LV function, neither of which we observed. The Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients with New York Heart Association Class III-IV Congestive Heart Failure (OPT-CHF) showed no clinical benefit of oxypurinol on an unselected cohort of HF patients with reduced ejection fraction, 19 but a post hoc analysis of hyperuricemic patients suggested a possible benefit with oxypurinol in this group. Post hoc, subgroup analyses, however, are hypothesis generating, and the results of the current study underscore the importance of prospective, randomized clinical trials to test such hypotheses.
Clinical trials are also inherently dependent on the study population enrolled. We aimed to enroll a group of high-risk patients with stable, chronic HF who were receiving excellent, guidelinerecommended therapy. 31 Patients had symptoms of HF for an average of 5 years, and more than half had been hospitalized for HF within the past year. In addition, they had multiple comorbidities, including diabetes mellitus and chronic kidney disease, and other high-risk features. Baseline quality-of-life scores and submaximal exercise capacity demonstrated significant impairment in HF status, similar to or worse than other recent studies. [32] [33] [34] Not surprisingly, the cumulative event rates in our study were high, with a ≈40% rate of death or all-cause hospitalization at 6 months. Importantly, our patients were adherent to study drug and follow-up, and all patients were included in the final analysis.
The target dose of allopurinol chosen in EXACT-HF was >6 times the bioequivalent dose of oxypurinol used in the OPT-CHF study, 19 with an expected ≥2-fold greater effect on UA lowering. 35 Previous data by George et al 15 demonstrated a dose-dependent effect of allopurinol on UA-lowering and endothelium-dependent vasodilation in chronic HF. On average, we observed a 45% reduction in UA levels in the active treatment arm by 12 weeks, and this effect was maintained at 24 weeks. However, we observed no change in myeloperoxidase levels raising the possibility that non-XO pathways of oxidative stress were activated and may have undermined the impact of our trial intervention. 3 Alternatively, other mechanisms that contribute to hyperuricemia in HF (eg, activation of proinflammatory cytokines) may have been unaffected by XO inhibition. Nitrates are beneficial in HF and may potentiate the benefit of XO inhibition. 36 However, an exploratory analysis †All P values are >0.05 for comparisons between the groups, with the exception of skin (P=0.02), rash (P=0.01), and vascular (P=0.04).
by guest on August 31, 2017 http://circ.ahajournals.org/ Downloaded from showed no difference between the primary and secondary end points in patients (n=79) who were taking nitrates at the time of randomization ( Table V in the online-only Data Supplement) .
Our study duration may not have been long enough to observe the benefits of XO inhibition. Notably, there was a trend toward reduced HF hospitalizations at 24 weeks, with a separation of the Kaplan-Meier curves beginning at ≈8 weeks ( Figure 4B ). We cannot exclude the possibility that a longer study of high-dose allopurinol in a more homogeneous group of high-risk patients would have demonstrated significant reductions in HF morbidity and mortality. Underpowering of the primary composite end point is possible given the modest sample size, whereas the possibility of a type II error cannot be ruled out. Our study groups were well matched at baseline, with the exception of a slightly higher LVEF in the allopurinol group (25.6% versus 23.4%), which could have biased results in favor of treatment.
With increasing recognition that nitroso-redox imbalance can affect cardiac structure and function, there may still be a role for XO inhibition in other cardiovascular disease states, including ischemic and hypertensive heart disease 37 and diabetic cardiomyopathy. 38 These studies suggest that reducing XO activity underlies the benefit of allopurinol. However, although decreased markers of oxidative stress have been demonstrated, these changes have not uniformly correlated with structural and functional improvements. More work is needed to understand the complex pathobiology underlying increased XO activity and the modifiable pathways of oxidative stress. 39 Our data confirm that allopurinol at doses up to 600 mg daily is safe and well tolerated in patients with HF even with accompanying renal dysfunction. Although cystatin C levels were significantly higher in the allopurinol group at 12 weeks, there was no difference at 24 weeks (and other markers of renal function did not differ between the treatment groups). In a single-center study of patients with gout and renal dysfunction, allopurinol use was associated with higher cystatin C levels. 40 It is speculated that cystatin C may be a marker of inflammation in addition to renal function, but this requires further study. Although rash occurred in 10% of allopurinoltreated patients, there were no reports of the allopurinol hypersensitivity syndrome, a rare but potentially fatal event, 41 and no cases of agranulocytosis or irreversible hepatotoxicity.
Conclusions
Despite accumulating evidence of the potential efficacy and safety of XO inhibition in cardiovascular disease states, in general, and HF, in particular, we found no clinical benefit of high-dose allopurinol in patients with HF, reduced ejection fraction, and elevated UA levels at 24 weeks. For patients at high risk of HF events, alternative therapies are needed.
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